<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131960</url>
  </required_header>
  <id_info>
    <org_study_id>MT-St-03</org_study_id>
    <nct_id>NCT03131960</nct_id>
  </id_info>
  <brief_title>Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB)</brief_title>
  <acronym>VNS-REHAB</acronym>
  <official_title>A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroTransponder Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ResearchPoint Global</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MicroTransponder Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pivotal phase study of up to 120 subjects and 15 clinical sites. All subjects are
      implanted with the Vivistim System® and then randomized to either study treatment or
      active-control treatment. The randomization will be stratified by age (&lt;30, &gt;30) and baseline
      FMA UE (20 to &lt;35; &gt;35 to 50). Study treatment is vagus nerve stimulation (VNS) delivered
      during rehabilitation. Active control treatment is rehabilitation (standard-of-care
      treatment) with only a minimal amount of VNS at the start of each session intended to support
      blinding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has three distinct stages: Stage I, an acute blinded stage, Stage II, an unblinded
      stage through one year of standard VNS, and Stage III, an unblinded stage for yearly
      follow-up after one year of VNS. The Control group crosses over to VNS treatment at Stage II.

      For Stage I, subjects have:

        -  consent and evaluation (screening),

        -  one pre-implant evaluation,

        -  surgical implant of the device system and randomization into one of the treatment arms,

        -  one baseline evaluation after device implant surgery but before initiation of treatment,

        -  6 weeks of treatment (standard-of-care rehabilitation + standard VNS or standard-of-care
           rehabilitation + active control VNS), and then

        -  post-acute therapy evaluations at 1, 30 and 90 days after the 6 weeks of treatment.

        -  Between Day 1 (V5) and Day 30 (V6) post-acute therapy, both groups will receive in-home,
           self-directed rehabilitation (30 minutes of daily rehabilitation as assigned by the
           therapist) with either in-home activated VNS (VNS group) or no VNS (Control group). This
           means that the control subjects will not have the in-home activated VNS until they
           complete the second 6-week session of in-clinic rehabilitation with follow-up
           assessments as described below in Stage II. At this point (Day 30) subjects start
           scheduling for their continuing long-term follow-up.

        -  Between Day 30 and Day 90 post-acute therapy, both groups continue in-home,
           self-directed rehabilitation (30 minutes of daily rehabilitation as assigned by the
           therapist). The VNS group continues to receive in-home VNS with magnet use; the Control
           group continues to use the magnet but does not receive any VNS. The Day 90 post-acute
           therapy visit is V7; it is the first quarterly visit (3 months after study therapy) for
           the VNS group and is the re-baseline visit (visit just prior to the initiation of
           standard VNS therapy) for the Control group.

      Stage II:

        -  VNS subjects will continue to have quarterly assessments through the end of the first
           year (6m, 9m, 12m).

        -  Subjects in the control group will crossover for a second 6-week in-clinic
           rehabilitation period where they will now receive rehabilitation with standard VNS.

        -  Control subjects will then have the three post therapy assessments (1, 30 and 90 days
           after therapy ends); in-home VNS initiated by a magnet swipe starts at the Post-1 visit
           (LT1). Thereafter, control subjects will follow the same schedule as VNS subjects for
           the remainder of the study (6m, 9m, 12m follow-ups, plus yearly visits thereafter).

        -  Subjects in both groups will receive &quot;booster&quot; in-clinic rehabilitation plus VNS therapy
           sessions one month prior to their 6- and 12-month assessment visits. These sessions
           occur on three days over a one-week period (typically Mon, Wed, Fri).

      Stage III:

      • After one year of standard VNS therapy (~13.5 months after implant for VNS group subjects
      and ~18 months after implant for Control group subjects), subjects who wish to keep their
      device for further use will have annual follow-up assessments until commercial approval.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, randomized, parallel study with partial crossover (control subjects crossover to treatment after randomized portion)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, therapists (care providers), investigators, and outcomes assessors do not know which group (VNS or control VNS) the patients are randomized. Only one person at the site - the programmer who programs the device settings - knows which group the subject is randomized into.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Assessment, Upper Limb (FM-A)</measure>
    <time_frame>V5, One day after 6-weeks of therapy</time_frame>
    <description>FM-A 1-day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment, Upper Limb (FM-A)</measure>
    <time_frame>V7, 90 days after 6-weeks of therapy</time_frame>
    <description>FM-A 90-day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment, Upper Limb (FM-A) Response</measure>
    <time_frame>V7, 90 days after 6-weeks of therapy</time_frame>
    <description>FM-A Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wolf Motor Function Test</measure>
    <time_frame>V7, 90 days after 6-weeks of therapy</time_frame>
    <description>WMFT 90-day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cerebrovascular Stroke</condition>
  <condition>Upper Extremity Paresis</condition>
  <arm_group>
    <arm_group_label>VNS + Rehabilitation (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control VNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paired Vagus Nerve Stimulation</intervention_name>
    <description>Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.</description>
    <arm_group_label>VNS + Rehabilitation (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rehabilitation</intervention_name>
    <description>Rehabilitation movements to improve upper limb function after stroke</description>
    <arm_group_label>VNS + Rehabilitation (1)</arm_group_label>
    <arm_group_label>Control VNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of unilateral supratentorial ischemic stroke that occurred at least 9 months
             but not more than ten 10 years prior to enrollment.

          2. Age &gt;22 years and &lt;80 years.

          3. FMA-UE score of 20 to 50 (inclusive of 20 and 50).

          4. Ability to communicate, understand, and give appropriate consent. Subjects should be
             able to follow two-step commands.

          5. Right- or left-sided weakness of upper extremity.

          6. Active wrist flexion/extension; active abduction/extension of thumb and at least two
             additional digits.

        Exclusion Criteria:

          1. History of hemorrhagic stroke

          2. Presence of ongoing dysphagia or aspiration difficulties.

          3. Subject receiving medication that may significantly interfere with the actions of VNS
             on neurotransmitter systems at study entry. A list of excluded medications will be
             provided to Investigators.

          4. Prior injury to vagus nerve, either bilateral or unilateral (e.g., injury during
             carotid endarterectomy).

          5. Severe or worse depression (Beck Depression Scale &gt; 29) (Beck et al., 1961)

          6. Unfavorable candidacy for device implant surgery (e.g., history of adverse reactions
             to anesthetics, poor surgical candidate in surgeon's opinion, etc.)

          7. Current use of any other stimulation device, such as a pacemaker or other
             neurostimulator; current use of any other investigational device or drug.

          8. Medical or mental instability (diagnosis of personality disorder, psychosis, or
             substance abuse) that would prevent subject from meeting protocol timeline.

          9. Pregnancy or plans to become pregnant or to breastfeed during the study period.

         10. Current requirement, or likely future requirement, of diathermy during the study
             duration.

         11. Active rehabilitation within 4 weeks prior to consent.

         12. Botox injections or any other non-study active rehabilitation of the upper extremity
             within 4 weeks prior to therapy through the post-30 day visit (Visit 6).

         13. Severe spasticity of the upper limb (Modified Ashworth ≥3) (Bohannon and Smith, 1987).

         14. Significant sensory loss. Sensory loss will be measured using the Upper Extremity
             sensory section of the Fugl Meyer Assessment of Physical Performance. The assessment
             addresses light touch (2 items) and proprioception (4 items).The highest points
             attained is 12; subjects with scores less than 6 will be excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brent Tarver, BSEE</last_name>
    <phone>512-371-4160</phone>
    <email>brent@microtransponder.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sue Lesly, BS</last_name>
    <phone>512-371-4160</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Perseverance Research Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Christians</last_name>
      <phone>480-471-6132</phone>
      <email>lchristians@prcresearcheducation.com</email>
    </contact>
    <investigator>
      <last_name>Allan Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rancho Research Institute</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Bayus</last_name>
      <phone>562-385-7049</phone>
      <email>nicoleb@ranchoresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Avina (para Espanol)</last_name>
      <phone>562) 385-7048</phone>
      <email>savina@ranchoresearch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Liu, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Jacksonville / Brooks Rehabilitation</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Munet-Diaz</last_name>
      <phone>904-953-3375</phone>
      <email>munet-diaz.veronica@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lou Demark</last_name>
      <phone>904-345-8968</phone>
      <email>Lou.Demark@brooksrehab.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ben Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lou Demark, PT, DPT, NCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Medical School</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Reiss</last_name>
      <phone>404-712-8685</phone>
      <email>aimee.reiss@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Murphy</last_name>
      <phone>404-712-1928</phone>
      <email>smurph7@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Wolf, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Peterson</last_name>
      <phone>617-643-6564</phone>
      <email>mpeterson6@mghihp.edu</email>
    </contact>
    <investigator>
      <last_name>Teresa Kimberley, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital / Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruchi Patel</last_name>
      <phone>212-746-1356</phone>
      <email>rup9005@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Michael O'Dell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Burke Medical Research Institute</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Tsargaris, MS</last_name>
      <phone>914-597-2153</phone>
      <email>kzt3001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Tomoko Kitago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Neuroscience Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Woodburn</last_name>
      <phone>614-366-7822</phone>
      <email>Erin.Woodburn@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Marcie Bockbrader, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Patino</last_name>
      <phone>215-955-2173</phone>
      <email>Maria.Patino@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Ash Sharan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Hutchison</last_name>
      <phone>843-792-2712</phone>
      <email>hutchis@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Wayne Feng, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melba Isom</last_name>
      <phone>615-875-5853</phone>
      <email>melba.isom@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Konrad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Kabamalan</last_name>
      <phone>214-648-2755</phone>
      <email>MariaPia.Kabamalan@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TIRR Memorial Hermann (UT Health Science Center at Houston)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruta Paranjape</last_name>
      <phone>713-799-6976</phone>
      <email>ruta.paranjape@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Francisco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Glasgow, Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela MacKenzie</last_name>
      <phone>+44 (0)141 451 5871</phone>
      <email>pamela.mackenzie@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jesse Dawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle (Royal Victoria Infirmary)</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Fawcett</last_name>
      <email>Michelle.Fawcett@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anand Dixit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vnsstroketrial.com</url>
    <description>Study recruiting website</description>
  </link>
  <reference>
    <citation>Porter BA, Khodaparast N, Fayyaz T, Cheung RJ, Ahmed SS, Vrana WA, Rennaker RL 2nd, Kilgard MP. Repeatedly pairing vagus nerve stimulation with a movement reorganizes primary motor cortex. Cereb Cortex. 2012 Oct;22(10):2365-74. doi: 10.1093/cercor/bhr316. Epub 2011 Nov 10.</citation>
    <PMID>22079923</PMID>
  </reference>
  <reference>
    <citation>Khodaparast N, Hays SA, Sloan AM, Fayyaz T, Hulsey DR, Rennaker RL 2nd, Kilgard MP. Vagus nerve stimulation delivered during motor rehabilitation improves recovery in a rat model of stroke. Neurorehabil Neural Repair. 2014 Sep;28(7):698-706. doi: 10.1177/1545968314521006. Epub 2014 Feb 18.</citation>
    <PMID>24553102</PMID>
  </reference>
  <reference>
    <citation>Hays SA, Khodaparast N, Ruiz A, Sloan AM, Hulsey DR, Rennaker RL 2nd, Kilgard MP. The timing and amount of vagus nerve stimulation during rehabilitative training affect poststroke recovery of forelimb strength. Neuroreport. 2014 Jun 18;25(9):676-82. doi: 10.1097/WNR.0000000000000154.</citation>
    <PMID>24818637</PMID>
  </reference>
  <reference>
    <citation>Dawson J, Pierce D, Dixit A, Kimberley TJ, Robertson M, Tarver B, Hilmi O, McLean J, Forbes K, Kilgard MP, Rennaker RL, Cramer SC, Walters M, Engineer N. Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke. 2016 Jan;47(1):143-50. doi: 10.1161/STROKEAHA.115.010477. Epub 2015 Dec 8.</citation>
    <PMID>26645257</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

